Pyderin’s choice as PDRN is trending

Unveiled raw material sources·purity·molecular size·skin delivery

Demonstrated possibility in improving skin metrics through human application

Min-Geon Kim, CEO of Pyderin, “Proven product efficacy in the global market”

Pyderin symposium landscape

Amid the rapid rise in PDRN products, Pyderin is demonstrating distinction in the market, highlighting its raw-material technology and studies on human application.

Rather than expanding its product lineup by riding trends, the company's strategy is to establish a trustworthy benchmark for pharmacists and consumers by scientifically validating PDRN's origin, purity, molecular size, and skin-delivery capacity.

​On July 21, Pyderin held the 'REDEFINE SYMPOSIUM' at Josun Palace in Seoul, unveiling the PDRN raw material technology and research findings applied to its products.

​"Not all PDRN Is created equal…raw material specifications are the starting point"

​First, CEO Hye Won Lim of Shebah Biotech described PDRN as a DNA-based biopolymer, emphasizing that the required characteristics of the raw material vary by application, including cosmetics, medical devices, and pharmaceuticals.

​PDRN is utilized across various sectors, including cosmetics, medical devices, and pharmaceuticals, based on its mechanisms of action, which involve anti-inflammation, cell and tissue regeneration, and angiogenesis. However, Lim explained that because required functionalities and applicable regulations differ by industry, it is difficult to apply a single raw material specification to all products uniformly.

​Cosmetics require a relatively small molecular size to facilitate skin delivery. Conversely, medical devices must also consider physical properties such as viscosity and skin retention time. This implies that technology engineered to tailor PDRN's molecular size to the product's intended use is essential.

​Under these circumstances, Pyderin used PDRN raw materials with molecular sizes specifically tailored for cosmetic applications. Rather than simply formulating the PDRN ingredient, the company engineered the size and specifications right from the raw material stage centering on skin delivery.

During the symposium, Pyderin highlighted the differentiation of the PDRN raw materials used in its products through a symposium booth.

CEO Lim stated, "PDRN for cosmetics must be designed in relatively smaller sizes for absorption, while PDRN for medical devices requires larger sizes for retention and viscosity," adding, "Technology that can adjust the raw material size according to the industry and product purpose is crucial."

​The raw material used in Pyderin products is also verified to confirm its biological species. After receiving the raw materials, Sheba Biotech verifies the salmonid species through genetic analysis, then purifies and adjusts the molecular size of the raw material for use in Pyderin products.

CEO Lim emphasized, "We utilize genetic analysis methods to distinguish whether the raw materials actually originate from salmon," and added, "Once the origin of the raw material is confirmed, we extract the DNA and process it according to the intended use of the product."

Human application studies confirm changes in skin metrics

​In the subsequent presentation, Dr. Ki Su Sung of Chungdam Jeunex Clinic (Director of the Korean Society for Obesity and Aesthetic Medicine) presented the results of a human application study evaluating the feasibility of applying PDRN formulations to the skin.

​The research team created micro-channels in the skin using a fractional laser and then applied the PDRN formulation. Subsequently, the treatment was repeated at set intervals, and changes in skin condition were evaluated.

​The study went beyond simple visual assessment to measure skin-related parameters such as wrinkle depth and pigmented area. Participant satisfaction and any adverse sensations or discomfort experienced during product use were also monitored.

Dr. Sung explained that major skin metrics improved after application of the PDRN formulation, and the improvement trend continued during follow-up. He added that virtually no distinct adverse reactions were reported during the study.

​A key feature of this study was the application of PDRN after creating skin delivery pathways via laser treatment. It explored the potential to overcome the skin-delivery limitations of large-molecule PDRN and to utilize it for post-dermatological-procedure recovery and care.

Dr. Sung explained that combining dermatological procedures with PDRN formulations and applying the product repeatedly could also assist in post-procedure skin management.

​(From left) Hye Won Lim, CEO of Shebah Biotech; Dr. Ki Su Sung of Chungdam Jeunex Clinic; Jung Bin Kim, Chief Medical Director of Chungdam Jeunex Clinic

​Dosage alone cannot judge topical PDRN

Jung Bin Kim, Chief Medical Director of Chungdam Jeunex Clinic, noted that while PDRN has emerged as a mainstream ingredient in the cosmetics market, the quality of the raw material and its skin-delivery efficacy can vary from product to product.

​This means that for topical PDRN to function effectively on the skin, it is not enough to simply blend the ingredient. Raw material purification, molecular size, application concentration, and delivery mechanism must all be scientifically engineered.

​Dr. Kim stated, "Topical PDRN is effective, but on one condition," adding that, "It must be purified and properly manufactured based on solid science. Simply producing it haphazardly will not yield results."

​PDRN has a relatively larger molecular size compared to general cosmetic ingredients like vitamin C. It is difficult to assume that a sufficient amount is delivered merely by applying it onto the skin surface; thus, the molecular size and formulation must be designed specifically for optimal skin absorption.

​Even if a product contains a high concentration of PDRN, if the actual percentage delivered into the skin is low, it is difficult to achieve the expected results. This is why product efficacy should be evaluated by examining the molecule size, concentration, and delivery system that can actually reach the skin, rather than judging by raw material content alone.

​Dr. Kim said, "The core criteria for selecting a good PDRN product come down to two factors: purity and molecular size," and highlighted, "Designing a smaller molecular size to enhance skin delivery and purifying the DNA raw material to high purity are where the true technological capabilities lie."

Pyderin was designed by increasing the purity of the PDRN raw materials and reducing their molecular size to suit cosmetic applications. During the presentation, it was also explained that Pyderin's raw material was engineered with a smaller molecular size than conventional PDRN raw materials.

​In particular, Dr. Kim evaluated this raw material engineering as the key driver in enhancing the skin delivery capacity of Pyderin's PDRN formulation.

He also introduced cases of Pyderin product use after dermatological laser and injection procedures. This approach manages skin dryness and irritation that may occur immediately after a procedure and supports the recovery of damaged skin through repeated applications thereafter.

​Accordingly, it was explained that this can serve as a rationale not only for post-procedure care at clinics but also for pharmacists to recommend appropriate products based on a consumer's skin condition and procedure history.

​"Validation, Not Trends"... Targeting global markets on a foundation of pharmacy trust

​Pyderin structured this symposium not merely as a product launch event but as a platform for disclosing raw material technology and research evidence.

Min-Geon Kim, CEO of Pyderin, defined the brand's starting point as "validation, not trends." He explained that establishing a steadfast standard over time by confirming the product's value through scientific evidence and data was the reason for launching Pyderin.

Min-Geon Kim, CEO of Pyderin

Community pharmacies were selcted for Pyderin as its initial distribution channel in November last year. According to CEO Kim, the products entered over 2,000 pharmacies nationwide within just eight months of launch.

​The company currently collaborates with Baekje Pharmaceutical, a domestic pharmaceutical distributor, to supply products to pharmacies.

​CEO Kim viewed this not merely as a count of store placements, but as the accumulated result of trust built with pharmacists who gave a new brand an opportunity.

​Furthermore, Pyderin disclosed that while it expanded into the Shinsegae Duty Free Myeongdong store in April this year to gauge consumer feedback, it withdrew just 45 days after entry due to concerns that expanding distribution channels might undermine the trust established with its existing pharmacy network.

​CEO Kim stated, "We believed that expanding into new channels should not compromise the value and trust of our existing network," adding, "Rather than focusing simply on selling more, we aim to become a brand that our partners can trust over the long term."

He added, "We will build a brand that pharmacists can confidently recommend as experts, and one where domestic and international partners can grow together believing in Pyderin's values and principles. We will prove our product capabilities in the global market."

​Amid intensifying competition in the PDRN market, Pyderin presented the origin and specifications of its raw materials, skin delivery efficiency, and human application evidence as its key differentiators.

In the future, how Pyderin specifically accumulates raw material test results and human application data, and connects them into actionable rationale for pharmacy settings, is expected to determine the success of its validation strategy.